Imugene picks peptide manufacturer for HER-Vaxx
Imugene (ASX:IMU) has appointed a peptide manufacturer for its HER-2+ cancer vaccine HER-Vaxx in advance of a phase II gastric cancer trial.
Swiss peptide chemistry company Bachem AG will conduct clinical-grade manufacturing for the peptide component of the HER-Vaxx therapeutic vaccine.
Bachem previously manufactured the peptides used for a phase I breast cancer trial, but the HER-Vaxx design has now changed to combine the three peptides used in this trial into a single, longer version.
Bachem has completed a successful feasibility test for this longer peptide and commenced manufacture of the peptide for the vaccine.
Commenting on the choice of partners, Imugene CEO Dr Nick Ede said that “over my 25 years in the global peptide community from both the scientific and business perspective, Bachem has been a constant in quality and experience”.
Imugene has already contracted Pevion Biotech to manufacture the HER-Vaxx vaccine itself.
HER-Vaxx stimulates a polyclonal antibody response to HER-2/neu, a cancer biomarker also targeted by the popular targeted cancer therapy Herceptin.
In Mach, Imugene commenced the process of filing an Investigational New Drug (IND) application for the treatment with the US FDA.
Imugene (ASX:IMU) shares were trading unchanged at $0.011 as of around 2 pm on Wednesday.
